Create a free account to unlock these features!
Track
 
5 users tracking
Nasdaq: GENZ   56.98 -0.62 (-1.08%)  Today2:45 PM ET
 
                   
Name: Genzyme Corp
Industries: Healthcare
Revenue: $4.52B ¹
Profit: $422.30M ¹
Employees: 11,000
Headquarters: ONE KENDALL SQ
CAMBRIDGE, Massachusetts 02139
United States Of America
Website:
¹ TTM figures for 31-Dec-2009
Genzyme gets to the heart of high-tech healthcare. Founded in 1981 and headquartered in Cambridge, MA, Genzyme Corporation (NASDAQ: GENZ) is a biotechnology company focusing on genetic disorders, renal disease, cancer, transplants, orthopedics, and diagnostic testing. It is also extending its reach into immune disease, infectious disease, and other areas. The company had 2008 revenue of about $4.6 billion and employs about 11,000 people. In November 12008, it announced a new research collaboration
Genzyme gets to the heart of high-tech healthcare. Founded in 1981 and headquartered in Cambridge, MA, Genzyme Corporation (NASDAQ: GENZ) is a biotechnology company focusing on genetic disorders, renal disease, cancer, transplants, orthopedics, and diagnostic testing. It is also extending its reach into immune disease, infectious disease, and other areas. The company had 2008 revenue of about $4.6 billion and employs about 11,000 people. In November 12008, it announced a new research collaboration with the International Center for Genetic Engineering and Biotechnology, a not-for-profit research and development (R&D) organization, to advance treatments for neglected diseases such as malaria.
... more
All News - 1000's of sources
loading news
 new tracked items.
Tracker changed. Refresh? yes | no
Sources
 
 
check at least one:
 
 
 
  
1212860 3/10/10:
PTC Therapeutics, Inc. and Genzyme Corporation Announce Preliminary ...
SOUTH PLAINFIELD, N.J. & CAMBRIDGE, Mass., Mar 03, 2010 (BUSINESS WIRE) -- PTC Therapeutics, Inc. and Genzyme Corporation /quotes/comstock/15*!genz/quotes/nls/genz (GENZ 57.23, 0.41, 0.72%) today announced preliminary results from the Phase 2b clinical trial of ataluren, an investigational new drug, ... - read more at BioSpace.com
1196506 3/8/10:
Medivation, Pfizer Disappointed Over Drug Failure - Biotech's ...
Pfizer (PFE)PFE) and Medivation (MDVN) said dimebon, their experimental drug to treat Alzheimer's disease, failed in two late-stage clinical trials. Medivation's stock, which had been trading at an all time high of $40.49 right before the news, tumbled nearly 70 percent to $13.04. In one trial, dimebon ... - read more at SeekingAlpha.com
1184604 3/4/10:
Science, Emotion, Costs of Healthcare Debate
I read an amazing, eye-opening story on Bloomberg.com this morning ("End-of-Life Warning at $618,616 Makes Me Wonder Was It Worth It") by a woman who told the tale of her family's seven-year struggle with illness. Her husband finally lost his battle with cancer in December of 2007, after many trials ... - read more at ONN.tv
1181152 3/4/10:
Genzyme drug fails to aid in walking
Genzyme Corp.'s experimental treatment for muscular dystrophy failed to meet the primary goal of a 48-week study. - read more at Boston Globe
tags: Genzyme 
1173532 3/3/10:
Genzyme (GENZ), PTC Therapeutics Report Prelim. Results from ...
Visit StreetInsider.com at http://www.streetinsider.com/FDA/Genzyme+%28GENZ%29%2C+PTC+Therapeutics+Report+Prelim.+Results+from+Phase+2b+Trial+of+Ataluren+for+nmDBMD/5403295.html for the full story. - read more at StreetInsider.com
tags: Genzyme (GENZ) 
1173449 3/3/10:
PTC Therapeutics and Genzyme Corporation Announce Preliminary ...
SOUTH PLAINFIELD, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--PTC Therapeutics, Inc. and Genzyme Corporation announced preliminary results from the Phase 2b clinical trial of ataluren. - read more at Business Wire
1173195 3/3/10:
The Incompetent Monopolist: Genzyme's Drug Screwups Invite Attacks ...
The FDA approved Shire (SHPGY)'s Gaucher disease drug, Vpriv, on Feb. 27, allowing the U.K. company to begin its planned destruction of Genzyme (GENZ)'s monopoly of the category. Genzyme is currently hobbled by its own incompetence and cannot produce its drugs at full capacity. - read more at BNET Business Network
tags: Genzyme  Shire 
1160528 3/1/10:
Shire Looks to Grab Market Share From Genzyme
FDA approval of Shire's (SHPGY) drug for Gaucher's disease comes as little surprise given that velaglucerase, now known as Vpriv, was already being administered to patients on an approved treatment protocol basis. That treatment protocol followed the well publicised manufacturing problems with the only ... - read more at SeekingAlpha.com
tags: Genzyme 
1157519 3/1/10:
Make 50% From Billionaire Carl Icahn's Latest Target (GENZ)
Carl Icahn is ready for a brawl... Back in October, we told you how a rogue virus had infected the manufacturing facilities of Genzyme, the biotech bellwether. The FDA ordered Genzyme to shut down its plant and cease producing Cerezyme and Fabrazyme, two of the company's most lucrative drugs. Revenue ... - read more at Benzinga
tags: GENZ  Carl Icahn 
1155088 3/1/10:
After a virus invades, Genzyme scrubs down
The virus hunters have arrived at Genzyme Corp. Dozens of decontamination specialists are busy stripping insulation from pipes at the company's biotech drug plant overlooking the Charles River in Allston. Their prep work involves dismantling equipment, peeling gaskets from the lids of 2,000-liter vats ... - read more at Boston Globe
Nasdaq: GENZ - Today2:45 PM ET
56.98 -0.62  (-1.08%)
Vol: 879.72K
High: 57.60
Low: 56.59
Mkt Cap: 15.16B
52Wk High: 63.47
52Wk Low: 47.09
P/E: 36.76
Div: 0.00
Yield: 0.00
1d | 1m | 3m | 6m | 1y | 5y | 10y
loading
previous day close
Financial Performance
Income (in thousands of USD) 3 months ending
2009-12-31
12 months ending
2009-12-31
Revenue 1,080,630 4,515,525
Net Income 23,245 422,300
Balance Sheet (in thousands of USD)
Current Assets 2,802,803 2,802,803
Total Assets 10,060,724 10,060,724
Current Liabilities 1,080,130 1,080,130
Total Liabilities 2,377,072 2,377,072
Total Shareholders Equity 7,683,652 7,683,652
Cash Flow (in thousands of USD)
Cash from Operating Activity 222,456 1,179,037
Cash from Investing Activity -184,343 -671,424
Cash from Financing Activity 26,521 -336,616
Change in Cash 62,687 170,140
Key Stats 3 months ending
2009-12-31
Trailing 12 Months
Gross Profit Margin 64.80% 69.30%
Net Profit Margin 2.15% 9.35%
Return on Assets 0.23% 4.20%
Return on Equity 0.30% 5.50%
Return on Invested Capital 0.21% 4.64%
© 2010 Tracked.com. All Rights Reserved.   About Us   |  Tour   |  Jobs   |  Contact Us   |  Terms of Use   |  Privacy Policy   |  Tracked.com Insights